Zoetis Inc. (ZTS) is currently trading at a high multiple, with a P/E ratio of over 40, higher than the industry average. Since investors believe Zoetis’ business to be encouraging, they value ZTS stock highly.
Top 5 EV Tech Stocks to Buy for 2023
According a new report published by BloombergNEF on investment in the energy transition, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now.
Click Here to Download the FREE Report.
Zoetis specializes in pharmaceutical products for the pets and livestock industry. Despite stagnating growth in feed and livestock, the last year was a very successful year for Zoetis owing to improvements in the pet and livestock segment (+17 % YoY). Global livestock demand declined due to a declining economy last year.
Simparica Trio – a remedy for parasites – was a growth driver for Zoetis Inc last year. This innovative product protects animals against some of the most common parasites, including ticks. In 2020, additional sales of the new drug totaled $ 150 million. A further $ 170 million was spent on medications to treat dermatological diseases, as pet owners devoted more attention to their pets during the coronavirus epidemic.
Zoetis Inc. (ZTS) plans to launch new medicines to the market in 2021 as a continued growth foundation. Dog and cat osteoarthritis treatment drugs Librela and Solensia will be on sale in the first half of the year. Based on monoclonal antibodies, they can reduce pain and improve joint mobility while causing minimal kidney and liver damage. A competitor is unlikely to be able to replicate this product in the veterinary industry.
The acquisition of Abaxis has further strengthened Zoetis’ diagnostic portfolio. This diagnostics suite from a commercially advanced diagnostic center can provide accurate, quick results. Zoetis will, however, continue to invest in this direction. Zoetis expects livestock to grow by single-digit percentages this year and pet products to grow by around 10%.
A share of Zoetis Inc. (ZTS) is trading at about $154.84, a price level that indicates its value has gone up 71.78% from its 52-week low. ZTS shares hit a high of $155.50 and a low of $152.50 in intraday trading. In the last 52 weeks, the ZTS stock’s shares have touched a high of $176.64 and a low of $90.14, with an intraday change of just 1.49%.